Last checked at 29 Aug 2012 14:00
Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global Investment Conference
-- 14th Annual Healthcare Conference --
Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, will present at the Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11, 2012 at The Waldorf Astoria, NY (USA).
The presentation is scheduled for Monday, 10 September 2012 at 16:30 Eastern Time. A copy of the slide presentation will be made available on the "Investors/Corporate presentations" section of the Company's website at www.oxfordbiomedica.co.uk.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications | Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications |
Tel: +44 (0)20 7920 2360
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.